



**NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.**

**Emerald Health Files Preliminary Base Shelf Prospectus**

**VICTORIA, BC, January 12, 2017 – Emerald Health Therapeutics Inc. (TSXV: EMH) (“Emerald” or the “Company”)** announces it has filed a base shelf prospectus (the “Prospectus”) with the securities regulatory authorities in the provinces of British Columbia and Alberta.

The Prospectus, when made final and effective, will enable the Company to make offerings of up to \$50,000,000 of common shares, preferred shares, debt securities, warrants, units or subscription receipts of the Company or a combination thereof from time to time, separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of the offering and as set out in an accompanying prospectus supplement, during the 25-month period that the Prospectus, when made final, remains effective. The specific terms of any future offering will be established in a prospectus supplement to the Prospectus, which supplement will be filed with the applicable Canadian securities regulatory authorities. The net proceeds from any sale of any securities will be used for purposes as set out in the applicable Prospectus supplement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.

A copy of the Prospectus can be found under the Company’s profile on [sedar.com](http://sedar.com) or may be obtained from the Company upon written request from the contact below.

**ON BEHALF OF THE BOARD**

**Jim Heppell**

**Lead Director**

**Emerald Health Therapeutics Inc.**

Emerald Health Therapeutics Inc. is a Licensed Producer under the *Access to Cannabis for Medical Purposes Regulations* (the “ACMPR”), authorized to cultivate and sell both dried medical cannabis flower and medical cannabis oils in Canada. Emerald currently operates out of an indoor facility in Victoria, British Columbia, with plans for a purpose built hybrid greenhouse expansion on 32 acres in metro

Vancouver. Emerald prides itself on being one of Canada's most medically focused producers with one of the industry's most qualified management teams with regard to pharmaceutical drug discovery, development and distribution. We aim to capture unique niches of both the medical and future recreational cannabis markets through proprietary strains, defensible intellectual property, and superb client and consumer experience.

### **Cautionary Statements Regarding Forward Looking Information**

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements regarding the filing and effectiveness of the final base shelf prospectus; the filing and effectiveness of any potential prospectus supplement and the amount and terms of any securities to be offered.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, the timing and filing of the final base shelf prospectus; the potential offering of any securities by the Company; uncertainty with respect to the completion of any future offering; the ability to obtain applicable regulatory approval for any contemplated offerings ; the ability of the Company to negotiate and complete future funding transactions; variations in market conditions; and other risk factors described in the Prospectus and the Company's other filings with the applicable Canadian securities regulators, which may be viewed at [www.sedar.com](http://www.sedar.com). Actual results may differ materially from those expressed or implied by such forward-looking statements.

### **Contact Information:**

Sandy Pratt  
CFO, Emerald Health Therapeutics  
P: 250-818-9838  
E: [sandy@emerald.care](mailto:sandy@emerald.care)